Drug Trial Radar · NCT03790085
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
Last checked: Nov 19, 2026Latest source record: Dec 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,700
Planned (sponsor's estimate)
Start
Sep 1, 2018
Primary completion
Jun 30, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Tianjin Medical University General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai Mental Health Center; Nanjing Medical University; Tianjin Anding Hospital; Harbin First Specialist Hospital; First Affiliated Hospital of Chongqing Medical University; Anhui Mental Health Center; Wuhan Psychiatric Hospital; Wenzhou Seventh People's Hospital; First Affiliated Hospital of Harbin Medical University
- First posted
- Dec 31, 2018
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.
Conditions
- Schizophrenia
- Major Depressive Disorder
- Anxiety Disorders
Interventions
RisperidoneDrug
Risperidone tablet
OlanzapineDrug
Olanzapine tablet
AripiprazoleDrug
Aripiprazole tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive and Negative Syndrome Scale (PANSS)Time frame: 30-45 minutes
- Clinical Global Impression(CGI)Time frame: 10-15 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University General Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.